Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Sattar, N.
Right arrow Articles by Petrie, J. R
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Type 2 diabetes as an inflammatory disorder

Naveed Sattar

Department of Pathological Biochemistry, Glasgow Royal Infirmary, Glasgow, G31 2ER, Scotland, UK, nsattar{at}clinmed.gla.ac.uk

Colin G Perry

John R Petrie

Although considerable research has addressed the potential role of inflammatory mediators in the pathogenesis of coronary heart disease, the relevance of this pathway to the pathogenesis of type 2 diabetes has only recently attracted interest. Circulating levels of inflammatory mediators correlate with insulin resistance and are significantly elevated in groups at risk of type 2 diabetes. Several prospective studies indicate that C-reactive protein and white cell count, together with other acute phase markers, predict incident diabetes independently of established predictors. Measures known to prevent diabetes (weight loss, exercise and metformin) and those more recently suggested (statins, ACE inhibitors and thiazolidinediones) have all been shown to exhibit anti-inflammatory actions. Mechanisms linking inflammation to diabetes development are beginning to be unravelled. Emerging knowledge of inflammatory mediators may help to predict those at risk of type 2 diabetes, and further work in this area may lead to novel means of prevention and treatment.

Key Words: coronary heart disease • cytokines • inflammation • type 2 diabetes • vascular endothelium.

References

  • Libby P., Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43.[Abstract/Free Full Text]
  • Rifai N., Ridker PM Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening. Clin Chem 2001;47:28-30.[Free Full Text]
  • Rothkrantz-Kos S., Schmitz MP, Bekers O., Menheere PP, van Dieijen-Visser MP High-sensitivity C-reactive protein methods examined. Clin Chem 2002;48:359-62.[Free Full Text]
  • Veselka J., Prochazkova S., Duchonova R. et al. Relationship of C-reactive protein to presence and severity of coronary atherosclerosis in patients with stable angina pectoris or a pathological exercise test. Coron Artery Dis 2002;13:151-4.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hill AG, Hill GL Metabolic response to severe injury. Br J Surg 1998;85: 884-90.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Mendall MA, Patel P., Ballam L., Strachan D., Northfield TC C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ 1996;312:1061-5.[Abstract/Free Full Text]
  • Pickup JC, Crook MA Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 1998;41:1241-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Wallace AM, McMahon AD, Packard CJ, Shepherd J., Gaw A., Sattar N. Plasma leptin and the risk of cardiovascular disease in the West of Scotland Coronary Prevention Study. Circulation 2001;104:3052-6.[Abstract/Free Full Text]
  • Cook DG, Mendall MA, Whincup PH et al. C-reactive protein concentration in children: relationship to adiposity and other cardiovascular risk factors. Atherosclerosis 2000;149:139-50.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kelly CCJ, Lyall H., Petrie JR, Gould GW, Connell JMC, Sattar N. Low-grade Chronic Inflammation in Women with PCOS. J Clin Endocrinol Metab 2001;86:2453-5.[Abstract/Free Full Text]
  • Forouhi NG, Sattar N., McKeigue P. Relation of C-reactive protein to cardiovascular risk factors in Europeans and South Asians. Int J Obesity 2001;25:1327-31.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Chambers JC, Eda S., Bassett P. et al. C-reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites. Circulation 2001; 104:145-50.[Abstract/Free Full Text]
  • Weyer C., Yudkin JS, Stehouwer CD, Schalkwijk CG, Pratley RE, Tataranni PA Humoral markers of inflammation and endothelial dysfunction in relation to adiposity and in vivo insulin action in Pima Indians. Atherosclerosis 2002;161:233-42.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Pannacciulli N., De Pergola G., Giorgino F., Giorgino R. A family history of Type 2 diabetes is associated with increased plasma levels of C-reactive protein in non-smoking healthy adult women. Diabet Med 2002;19:689-92.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Wannamethee SG, Lowe GD, Whincup PH, Rumley A., Walker M., Lennon L. Physical activity and hemostatic and inflammatory variables in elderly men. Circulation 2002;105:1785-90.[Abstract/Free Full Text]
  • Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999;19:972-8.[Abstract/Free Full Text]
  • Festa A., D'Agostino R. Jr, Howard G., Mykkanen L., Tracy RP, Haffner SM Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102:42-7.[Abstract/Free Full Text]
  • Schmidt MI, Duncan BB, Sharrett AR et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 1999;353:1649-52.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Nakanishi N., Yoshida H., Matsuo Y., Suzuki K., Tatara K. White blood-cell count and the risk of impaired fasting glucose or Type II diabetes in middle-aged Japanese men. Diabetologia 2002;45:42-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Vozarova B., Weyer C., Lindsay RS, Pratley RE, Bogardus C., Tataranni PA High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002;51:455-61.[Abstract/Free Full Text]
  • Pradhan AD, Manson JE, Rifai N., Buring JE, Ridker PM C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327-34.[Abstract/Free Full Text]
  • Barzilay JI, Abraham L., Heckbert SR et al. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes 2001;50:2384-9.[Abstract/Free Full Text]
  • Freeman DJ, Norrie J., Caslake M. et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002;51:1596-600.[Abstract/Free Full Text]
  • Festa A., D'Agostino R. Jr, Tracy RP, Haffner SM The Insulin Resistance Atherosclerosis Study. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002;51: 1131-7.[Abstract/Free Full Text]
  • Lindsay RS, Funahashi T., Hanson RL et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002;360:57-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Temelkova-Kurktschiev T., Siegert G., Bergmann S. et al. Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetes. Metabolism 2002;51: 743-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Mohamed-Ali V., Pinkney JH, Coppack SW Adipose tissue as an endocrine and paracrine organ. Int J Obes 1998;22:1145-58.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hotamisligil GS, Shargill NS, Spiegelman BM Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993;259:87-91.[Abstract/Free Full Text]
  • Ofei F., Hurel S., Newkirk J., Sopwith M., Taylor R. Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 1996;45:881-5.[Abstract]
  • Paquot N., Castillo MJ, Lefebvre PJ, Scheen AJ No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients. J Clin Endocrinol Metab 2000;85:1316-19.[Abstract/Free Full Text]
  • Bastard JP, Jardel C., Bruckert E. et al. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 2000;85:3338-42.[Abstract/Free Full Text]
  • Dovio A., Angeli A. Cytokines and type 2 diabetes mellitus. JAMA 2001;286:2233.[Free Full Text]
  • Khovidhunkit W., Memon RA, Feingold KR, Grunfeld C. Infection and inflammation-induced proatherogenic changes of lipoproteins. J Infect Dis 2000;181(suppl 3):S462-72.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Björntorp P. Fatty acids, hyperinsulinemia, and insulin resistance: which comes first? Curr Opin Lipidol 1994;5:166-74.[Medline] [Order article via Infotrieve]
  • Steinberg HO, Baron AD, Steinberg H. et al.: Vascular function, insulin resistance and fatty acids. Diabetologia 2002;45:623-34.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Vallance P., Collier J., Bhagat K. Infection, inflammation, and infarction: does acute endothelial dysfunction provide a link? Lancet 1997;349: 1391-2.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Cleland SJ, Sattar N., Petrie JR, Forouhi NG, Elliot H., McConnell JMC. Sensitive C-reactive protein and basal endothelial function. Clinical Science 2000;98:531-35.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • van Exel E., Gussekloo J., de Craen AJ et al. Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes: the Leiden 85-Plus Study. Diabetes 2002;51:1088-92.[Abstract/Free Full Text]
  • Gunnett CA, Heistad DD, Faraci FM Interleukin-10 protects nitric oxide-dependent relaxation during diabetes: role of superoxide. Diabetes 2002; 51:1931-7.[Abstract/Free Full Text]
  • Walder K., Kantham L., McMillan JS et al. Tanis: a link between type 2 diabetes and inflammation? Diabetes 2002;51:1859-66.[Abstract/Free Full Text]
  • Kim JK, Kim YJ, Fillmore JJ et al. Prevention of fat-induced insulin resistance by salicylate. J Clin Invest 2001;108:437-46.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Yang WS, Lee WJ, Funahashi T. et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001;86:3815-19.[Abstract/Free Full Text]
  • Hotta K., Funahashi T., Bodkin NL et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 2001;50:1126-33.[Abstract/Free Full Text]
  • Knowler WC, Barrett-Connor E., Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.[Abstract/Free Full Text]
  • Tuomilehto J., Lindström J., Erickson JG et al., for the Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Eng J Med 2001;344:1343-50.[Abstract/Free Full Text]
  • Freeman DJ, Norrie J., Sattar N. et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001;103:357-62.[Abstract/Free Full Text]
  • Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.[Abstract/Free Full Text]
  • Hansson L., Lindholm LH, Niskanen L. et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999;353:611-16.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Tchernof A., Nolan A., Sites CK, Ades PA, Poehlman ET Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation 2002;105:564-9.[Abstract/Free Full Text]
  • Ridker PM, Rifai N., Pfeffer MA, Sacks F., Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999; 100:230-5.[Abstract/Free Full Text]
  • Gullestad L., Aukrust P., Ueland T. et al. Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J Am Coll Cardiol 1999;34:2061-7.[Abstract/Free Full Text]
  • Haffner SM, Greenberg AS, Weston WM, Chen H., Williams K., Freed MI Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106:679-84.[Abstract/Free Full Text]

The British Journal of Diabetes & Vascular Disease, Vol. 3, No. 1, 36-41 (2003)
DOI: 10.1177/14746514030030010501
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 HeartHome page
C G Perry, S J Cleland, J M Connell, J R Petrie, and N Sattar
Low grade inflammation is notably suppressed by conventional anti-inflammatory treatment: a randomised crossover trial
Heart, July 1, 2004; 90(7): 804 - 805.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Sattar, N.
Right arrow Articles by Petrie, J. R
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?